Moffitt Cancer Center Logo
 

Jongphil Kim, PhD

Where You Are:
Jongphil Kim, PhD

Assistant Member

"My primary research interest involves the multiple comparisons, longitudinal data analysis, categorical data analysis and survival analysis."

Office  (813) 745-6908

Education And Training
  • PhD, Georgia Institute of Technology, 2007 - Industrial & Systems Engineering with Applied Statistics
  • MS, Georgia Institute of Technology, 2006 - Statistics
  • MS, Georgia Institute of Technology, 2001 - Industrial Engineering
  • MS, Pusan National University, 1995 - Mechanical Engineering
  • BS, Pusan National University, 1993 - Mechanical Engineering


My primary areas of expertise in statistics include image data analysis, survival analysis, clinical trials, multiple comparisons, and longitudinal data analysis. I am a co-investigator in research projects funded from both the NIH and the ACS. I have collaborated with oncologists in bone marrow transplant and lung cancer, scientists in image programs, and epidemiologists

  • Latifi K, Oliver J, Baker R, Dilling TJ, Stevens CW, Kim J, Yue B, Demarco M, Zhang GG, Moros EG, Feygelman V. Study of 201 non-small cell lung cancer patients given stereotactic ablative radiation therapy shows local control dependence on dose calculation algorithm. Int J Radiat Oncol Biol Phys. 2014 Apr;88(5):1108-1113. Pubmedid: 24529716.
  • Nishihori T, Perkins J, Mishra A, Komrokji R, Kim J, Kharfan-Dabaja MA, Perez L, Lancet J, Fernandez H, List A, Anasetti C, Field T. Pretransplantation 5-Azacitidine in High-Risk Myelodysplastic Syndrome. Biol Blood Marrow Transplant. 2014 Feb. Pubmedid: 24534108.
  • Han G, Schell MJ, Kim J. Improved survival modeling in cancer research using a reduced piecewise exponential approach. Stat Med. 2014 Jan;33(1):59-73. Pubmedid: 23900779.
  • Pal T, Vadaparampil S, Kim J, Xu Y, Friedman S, Narod SA, Metcalfe K. Interest of individuals from BRCA families to participate in research studies focused on male BRCA carriers. Fam Cancer. 2013 Dec;12(4):615-619. Pubmedid: 23504063.
  • Kim J, Lee JH. Simultaneous confidence intervals for a success probability and intraclass correlation, with an application to screening mammography. Biometrical J. 2013 Nov;55(6):944-954. Pubmedid: 24115052.
  • Williams M, Eatrides J, Kim J, Talwar H, Esposito N, Szabunio M, Ismail-Khan R, Kiluk J, Lee M, Laronga C, Khakpour N. Comparison of breast magnetic resonance imaging clinical tumor size with pathologic tumor size in patients status post-neoadjuvant chemotherapy. Am J Surg. 2013 Oct;206(4):567-573. Pubmedid: 23809673.
  • Veerapathran A, Pidala J, Beato F, Betts B, Kim J, Turner JG, Hellerstein MK, Yu XZ, Janssen W, Anasetti C. Human regulatory T cells against minor histocompatibility antigens: ex vivo expansion for prevention of graft-versus-host disease. Blood. 2013 Sep;122(13):2251-2261. Pubmedid: 23908471. Pmcid: PMC3785121.
  • Pal T, Bonner D, Kim J, Monteiro AN, Kessler L, Royer R, Narod SA, Vadaparampil ST. Early onset breast cancer in a registry-based sample of African-american women: BRCA mutation prevalence, and other personal and system-level clinical characteristics. Breast J. 2013 Sep;19(2):189-192. Pubmedid: 23320992.
  • Pal T, Cragun D, Lewis C, Doty A, Rodriguez M, Radford C, Thompson Z, Kim J, Vadaparampil ST. A statewide survey of practitioners to assess knowledge and clinical practices regarding hereditary breast and ovarian cancer. Genet Test Mol Biomarkers. 2013 May;17(5):367-375. Pubmedid: 23448386.
  • Nishihori T, Ochoa-Bayona JL, Kim J, Pidala J, Shain K, Baz R, Sullivan D, Jim HS, Anasetti C, Alsina M. Allogeneic hematopoietic cell transplantation for consolidation of VGPR or CR for newly diagnosed multiple myeloma. Bone Marrow Transplant. 2013 Apr;48(9):1179-1184. Pubmedid: 23542223.
  • Pidala J, Kim J, Schell M, Lee SJ, Hillgruber R, Nye V, Ayala E, Alsina M, Betts B, Bookout R, Fernandez HF, Field T, Locke FL, Nishihori T, Ochoa JL, Perez L, Perkins J, Shapiro J, Tate C, Tomblyn M, Anasetti C. Race/ethnicity affects the probability of finding an HLA-A, -B, -C and -DRB1 allele-matched unrelated donor and likelihood of subsequent transplant utilization. Bone Marrow Transplant. 2013 Mar;48(3):346-350. Pubmedid: 22863723.
  • Kumar V, Nath K, Berman CG, Kim J, Tanvetyanon T, Chiappori AA, Gatenby RA, Gillies RJ, Eikman EA. Variance of SUVs for FDG-PET/CT is greater in clinical practice than under ideal study settings. Clin Nucl Med. 2013 Mar;38(3):175-182. Pubmedid: 23354032. Pmcid: PMC3578161.
  • Kim J. The computation of bivariate normal and t probabilities, with application to comparisons of three normal means. Comput Stat Data Anal. 2013 Feb;58:177-186.
  • Pidala J, Kim J, Jim H, Kharfan-Dabaja MA, Nishihori T, Fernandez HF, Tomblyn M, Perez L, Perkins J, Xu M, Janssen WE, Veerapathran A, Betts BC, Locke FL, Ayala E, Field T, Ochoa L, Alsina M, Anasetti C. A randomized phase II study to evaluate tacrolimus in combination with sirolimus or methotrexate after allogeneic hematopoietic cell transplantation. Haematologica. 2012 Dec;97(12):1882-1889. Pubmedid: 22689677.
  • Han G, Schell MJ, Kim J. Comparing Two Exponential Distributions Using the Exact Likelihood Ratio Test. Stat Biopharm Res. 2012 Oct;4(4):348-356. Pubmedid: 23814641.
  • Perkins JB, Kim J, Anasetti C, Fernandez HF, Perez LE, Ayala E, Kharfan-Dabaja MA, Tomblyn MR, Sullivan DM, Pidala JA, Field TL. Maximally tolerated busulfan systemic exposure in combination with fludarabine as conditioning before allogeneic hematopoietic cell transplantation. Biol Blood Marrow Tran. 2012 Jul;18(7):1099-1107. Pubmedid: 22198540.
  • Nishihori T, Alekshun TJ, Shain K, Sullivan DM, Baz R, Perez L, Pidala J, Kharfan-Dabaja MA, Ochoa-Bayona JL, Fernandez HF, Yarde DN, Oliveira V, Fulp W, Han G, Kim J, Chen DT, Raychaudhuri J, Dalton W, Anasetti C, Alsina M. Bortezomib salvage followed by a Phase I/II study of bortezomib plus high-dose melphalan and tandem autologous transplantation for patients with primary resistant myeloma. Br J Haematol. 2012 Jun;157(5):553-563. Pubmedid: 22449149.
  • Simon GR, Schell MJ, Begum M, Kim J, Chiappori A, Haura E, Antonia S, Bepler G. Preliminary indication of survival benefit from ERCC1 and RRM1-tailored chemotherapy in patients with advanced nonsmall cell lung cancer: evidence from an individual patient analysis. Cancer. 2012 May;118(9):2525-2531. Pubmedid: 22028294. Pmcid: PMC3270127.
  • Pidala J, Kim J, Anasetti C, Nishihori T, Betts B, Field T, Perkins J. The global severity of chronic graft-versus-host disease, determined by National Institutes of Health consensus criteria, is associated with overall survival and non-relapse mortality. Haematologica. 2012 Feb;96(11):1678-1684. Pubmedid: 21791465. Pmcid: PMC3208686.
  • Perkins JB, Goldstein SC, Dawson JL, Kim J, Field TL, Partyka JS, Fields KK, Maddox BL, Simonelli CE, Neuger AM, Lush RM, Sullivan DM. Phase I Study of Topotecan, Ifosfamide, and Etoposide (TIME) with autologous stem cell transplant in refractory cancer: pharmacokinetic and pharmacodynamic correlates. Clin Cancer Res. 2011 Dec;17(24):7743-7753. Pubmedid: 22028494.
  • Perkins J, Field T, Kim J, Kharfan-Dabaja MA, Ayala E, Perez L, Fernandez H, Fancher K, Tate C, Shaw LM, Milone MC, Gardiner JA, Miller S, Anasetti C. Pharmacokinetic targeting of i.v. BU with fludarabine as conditioning before hematopoietic cell transplant: the effect of first-dose area under the concentration time curve on transplant-related outcomes. Bone Marrow Transplant. 2011 Nov;46(11):1418-1425. Pubmedid: 21132026.
  • Pidala J, Lee SJ, Quinn G, Jim H, Kim J, Anasetti C. Variation in management of immune suppression after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2011 Oct;17(10):1528-1536. Pubmedid: 21440079.
  • Kiluk JV, Lee MC, Park CK, Meade T, Minton S, Harris E, Kim J, Laronga C. Male Breast Cancer: Management and Follow-up Recommendations. Breast J. 2011 Sep;17(5):503-509. Pubmedid: 21883641.
  • Patel M, Hoffe S, Malafa M, Hodul P, Klapman J, Centeno B, Kim J, Helm J, Valone T, Springett G. Neoadjuvant GTX chemotherapy and IMRT-based chemoradiation for borderline resectable pancreatic cancer. J Surg Oncol. 2011 Aug;104(2):155-161. Pubmedid: 21520097. Pmcid: PMC3347705.
  • Pidala J, Kim J, Anasetti C, Kharfan-Dabaja MA, Field T, Perkins J, Ayala E, Perez L, Fernandez H. Targeted i.v. BU and fludarabine (t-i.v. BU/Flu) provides effective control of AML in adults with reduced toxicity. Bone Marrow Transplant. 2011 May;46(5):641-649. Pubmedid: 20711242.
  • Tafreshi NK, Enkemann SA, Bui MM, Lloyd MC, Abrahams D, Huynh AS, Kim J, Grobmyer SR, Carter WB, Vagner J, Gillies RJ, Morse DL. A mammaglobin-A targeting agent for noninvasive detection of breast cancer metastasis in lymph nodes. Cancer Res. 2011 Feb;71(3):1050-1059. Pubmedid: 21169406.
  • Pidala J, Roman-Diaz J, Kim J, Nishihori T, Perkins J, Tate C, Ochoa-Bayona JL, Field T, Fernandez HF, Tomblyn M, Ayala E, Anasetti C, Kharfan-Dabaja MA. Targeted IV busulfan and fludarabine followed by post-allogeneic hematopoietic cell transplantation rituximab demonstrate encouraging activity in CD20+ lymphoid malignancies without increased risk of infectious complications. Int J Hematol. 2011 Feb;93(2):206-212. Pubmedid: 21246311.
  • Pidala J, Kim J, Kharfan-Dabaja MA, Nishihori T, Field T, Perkins J, Perez L, Fernandez H, Anasetti C. Dysglycemia following glucocorticoid therapy for acute graft-versus-host disease adversely affects transplantation outcomes. Biol Blood Marrow Tran. 2011 Feb;17(2):239-248. Pubmedid: 20637884.
  • Pidala J, Kim J, Anasetti C, Kharfan-Dabaja MA, Nishihori T, Field T, Perkins J, Perez L, Fernandez HF. Pharmacokinetic targeting of intravenous busulfan reduces conditioning regimen related toxicity following allogeneic hematopoietic cell transplantation for acute myelogenous leukemia. J Hematol Oncol. 2011 Jan;3:36. Pubmedid: 20925957. Pmcid: PMC2958877.
  • Nishihori T, Perkins J, Kim J, Field T, Pidala J, Roman-Diaz J, Komrokji RS, Fernandez HF, Anasetti C, Kharfan-Dabaja MA. Allogeneic hematopoietic cell transplantation for myelofibrosis: a 10-year experience at single institution. Am J Hematol. 2010 Nov;85(11):904-907. Pubmedid: 20890908.
  • Gwede CK, William CM, Thomas KB, Tarver WL, Quinn GP, Vadaparampil ST, Kim J, Lee JH, Meade CD. Exploring disparities and variability in perceptions and self-reported colorectal cancer screening among three ethnic subgroups of U. S. Blacks. Oncol Nurs Forum. 2010 Sep;37(5):581-591. Pubmedid: 20797950. Pmcid: PMC2946332.
  • Hoda D, Pidala J, Salgado-Vila N, Kim J, Perkins J, Bookout R, Field T, Perez L, Ayala E, Ochoa-Bayona JL, Raychaudhuri J, Alsina M, Greene J, Janssen W, Fernandez HF, Anasetti C, Kharfan-Dabaja MA. Sirolimus for treatment of steroid-refractory acute graft-versus-host disease. Bone Marrow Transplant. 2010 Aug;45(8):1347-1351. Pubmedid: 19966849.
  • Perkins J, Field T, Kim J, Kharfan-Dabaja MA, Fernandez H, Ayala E, Perez L, Xu M, Alsina M, Ochoa L, Sullivan D, Janssen W, Anasetti C. A randomized phase II trial comparing tacrolimus and mycophenolate mofetil to tacrolimus and methotrexate for acute graft-versus-host disease prophylaxis. Biol Blood Marrow Tran. 2010 Jul;16(7):937-947. Pubmedid: 20102746.
  • Tanvetyanon T, Robinson L, Sommers KE, Haura E, Kim J, Altiok S, Bepler G. Relationship between Tumor Size and Survival among Patients with Resection of Multiple Synchronous Lung Cancers. J Thorac Oncol. 2010 Jul;5(7):1018-1024. Pubmedid: 20453687.
  • Pidala J, Kim J, Perkins J, Field T, Fernandez H, Perez L, Ayala E, Kharfan-Dabaja M, Anasetti C. Mycophenolate mofetil for the management of steroid-refractory acute graft vs host disease. Bone Marrow Transplant. 2010 May;45(5):919-924. Pubmedid: 19767783.
  • Nyitray AG, Kim J, Hsu CH, Papenfuss M, Villa L, Lazcano-Ponce E, Giuliano AR. Test-retest reliability of a sexual behavior interview for men residing in Brazil, Mexico, and the United States: the HPV in Men (HIM) Study. Am J Epidemiol. 2009 Oct;170(8):965-974. Pubmedid: 19741044. Pmcid: PMC2765366.
  • Pidala J, Kim J, Field T, McBride A, Kharfan-Dabaja M, Perkins J, Fernandez H, Perez L, Ayala E, Anasetti C. Infliximab for managing steroid-refractory acute graft-versus-host disease. Biol Blood Marrow Transplant. 2009 Sep;15(9):1116-1121. Pubmedid: 19660725.
  • Pidala J, Kim J, Anasetti C. Sirolimus as primary treatment of acute graft-versus-host disease following allogeneic hematopoietic cell transplantation. Biol Blood Marrow Tran. 2009 Jul;15(7):881-885. Pubmedid: 19539221.
  • Munster P, Marchion D, Bicaku E, Lacevic M, Kim J, Centeno B, Daud A, Neuger A, Minton S, Sullivan D. Clinical and biological effects of valproic acid as a histone deacetylase inhibitor on tumor and surrogate tissues: phase I/II trial of valproic acid and epirubicin/FEC. Clin Cancer Res. 2009 Apr;15(7):2488-2496. Pubmedid: 19318486.
  • Ganesh S, Hayter A, Kim J, Sanford J, Sprigle S, Hoenig H. Wheelchair use by veterans newly prescribed a manual wheelchair. Arch Phys Med Rehabil. 2007 Apr;88(4):434-439. Pubmedid: 17398243.
  • Pidala J, Kim J, Roman-Diaz J, Shapiro J, Nishihori T, Bookout R, Anasetti C, Kharfan-Dabaja MA. Pentostatin as rescue therapy for glucocorticoid-refractory acute and chronic graft-versus-host disease. Ann Transplant. 15(4):21-29. Pubmedid: 21183872.
TOOLS:   Font Size small font resizer separator font resizer separator big font resizer